Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: a case series.

BACKGROUND Clearance of circulating myoglobin is a critical measure to prevent further damage in patients with rhabdomyolysis (RM) and acute kidney injury (AKI). Continuous venous-venous haemofiltration has emerged to be a novel approach for this purpose. The objective of present study is to evaluate the efficacy and safety of CVVH in myoglobin clearance for patients with RM complicated with AKI. METHOD We prospectively analysed 15 patients with acute RM and AKI due to crush syndrome (n=7), bee stings (n=5), polymyositis (n=2) and heroin poisoning (n=1). All of them presented oliguria with high serum myoglobin and creatine kinase concentration. They were treated by CVVH for at least 48h until the conditions turned to be stable, then replaced by intermittent renal replacement therapy (intermittent haemofiltration or haemodialysis). Meanwhile intravascular volume expansion, urinary alkalinisation, and forced diuresis were administered. During the procedure, serum and effluent concentrations of myoglobin and creatinine were measured simultaneously at 2, 6, 12 and 24h. RESULT The mean sieving coefficients for myoglobin were 0.28±0.06, 0.21±0.06, 0.15±0.02 and 0.11±0.02 during 2, 6, 12 and 24h of CVVH intervention, whilst mean clearance of myoglobin was 14.3±3.1ml/min during 2h and reduced to 11.5±3.2, 7.5±0.9, 5.6±1.0ml/min during 6, 12 and 24h. In contrast to myoglobin, the sieving coefficient for creatinine remained stable at 0.95±0.25, 1.02±0.12, 0.89±0.32, 0.98±0.27 during 24h of CVVH. In all of the 15 patients, serum myoglobin and creatine kinase were dramatically decreased in 24h (-56.2 and -32.1%), 3 days (-72.9 and -50.3%) and in 7 days (-97.6 and -96.7%). Seven patients (46.7%) complicated with hypophosphatemia during CVVH intervention improved in natural course after the cessation of CVVH. After 16±12 days, all of 15 patients came to polyuria stage and finally, discharged with normal renal function after 31±15 days. CONCLUSION Our study showed CVVH can be employed to clear myoglobin effectively in patients with RM and AKI and presented oliguria. This indicate that CVVH would be better than other modes of renal replement treatment in acute RM with AKI because of the additional benefit of myoglobin removal, but large sample randomised controlled trials are still required to confirm it.

[1]  R. Pålsson,et al.  Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. , 1999, Kidney international.

[2]  R. Vanholder,et al.  Renal replacement therapies in the aftermath of the catastrophic Marmara earthquake. , 2002, Kidney international.

[3]  P. Toft,et al.  Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis , 2005, Acta anaesthesiologica Scandinavica.

[4]  V. Pettilä,et al.  The effect of combining intermittent hemodiafiltration with forced alkaline diuresis on plasma myoglobin in rhabdomyolysis , 2007, Acta anaesthesiologica Scandinavica.

[5]  E. Poch,et al.  Rhabdomyolysis and acute kidney injury. , 2009, The New England journal of medicine.

[6]  R. Zager,et al.  Rhabdomyolysis and myohemoglobinuric acute renal failure. , 1996, Kidney international.

[7]  C. Ronco Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance , 2005, Critical care.

[8]  M. Leblanc,et al.  Myoglobin clearance and removal during continuous venovenous hemofiltration , 1999, Intensive Care Medicine.

[9]  H. Rinka,et al.  Blood purification for crush syndrome. , 1997, Renal failure.

[10]  R. Bellomo,et al.  Acute Renal Failure and Multiple Organ Dysfunction in the ICU: From Renal Replacement Therapy (RRT) to Multiple Organ Support Therapy (MOST) , 2002, The International journal of artificial organs.

[11]  R. Bellomo,et al.  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group , 2004, Critical care.

[12]  R. Bellomo,et al.  Continuous renal replacement therapy: A worldwide practice survey , 2007, Intensive Care Medicine.

[13]  W. Kox,et al.  Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder. , 2001, Anesthesiology.

[14]  Y. Chatzizisis,et al.  The syndrome of rhabdomyolysis: complications and treatment. , 2008, European journal of internal medicine.

[15]  Daryl A Jones,et al.  Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report , 2005, Critical care.

[16]  N. Boyce,et al.  Myoglobin clearance during acute continuous hemodiafiltration , 2005, Intensive Care Medicine.

[17]  Joseph Varon,et al.  Bench-to-bedside review: Rhabdomyolysis – an overview for clinicians , 2004, Critical care.

[18]  R. Bellomo,et al.  Pre-Dilution vs. Post-Dilution during Continuous Veno-Venous Hemofiltration: Impact on Filter Life and Azotemic Control , 2003, Nephron Clinical Practice.